OVID · XBRL financial data

Ovid Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OVID's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	208,383	1,503	392	566	7,252
Research and development	63,417	46,940	24,618	28,588	36,767	25,582
General and administrative	30,631	37,234	32,433	31,085	25,684	24,109
Total operating expenses	94,048	84,174	57,051	59,673	62,451	49,691
Other operating income (expense)	395	(46)	—	—	—	—
Operating income (loss)	(81,431)	124,209	(55,548)	(59,281)	(61,885)	(42,439)
Interest income	—	—	—	4,940	3,915	2,026
Other income (expense)	—	(46)	1,379	6,943	35,452	25,026
Income tax expense (benefit)	0	1,329	0	0	0	0
Net income (loss)	(81,036)	122,835	(54,169)	(52,339)	(26,433)	(17,414)
Earnings per share, basic USD per share	(1.39)	1.78	(0.77)	(0.74)	—	—
Earnings per share, diluted USD per share	(1.39)	1.76	(0.77)	(0.74)	—	—
Weighted average shares, basic thousands of shares	58,451	67,479	70,425	70,581	—	—
Weighted average shares, diluted thousands of shares	58,451	68,068	70,425	70,581	—	—

Fiscal years (OVID's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	72,034	187,798	44,868	27,042	26,301	13,153
Marketable securities	—	0	84,134	78,792	26,774	56,482
Marketable securities, non-current	—	—	—	—	0	20,812
Prepaid and other current assets	2,668	2,682	2,379	3,764	2,865	4,733
Total current assets	74,843	190,479	131,381	109,598	55,940	74,368
Property and equipment, net	136	243	1,148	769	433	252
Right-of-use asset	—	0	14,923	13,894	12,797	11,610
Total assets	75,926	194,545	155,266	144,027	92,167	150,934
Accounts payable	5,446	7,127	1,953	3,703	3,191	1,956
Accrued liabilities	12,033	7,671	4,505	6,525	5,994	4,899
Total current liabilities	22,063	14,798	6,992	11,474	10,522	8,288
Lease liability, non-current	—	0	16,002	14,756	13,419	11,986
Total liabilities	32,294	14,798	22,993	56,230	23,941	20,274
Accumulated deficit	(294,192)	(171,358)	(225,527)	(277,866)	(304,299)	(321,713)
Total stockholders' equity	43,632	179,746	132,273	87,797	68,226	130,660
Total liabilities and equity	75,926	194,545	155,266	144,027	92,167	150,934
Common shares outstanding (cover page) thousands of shares	65,754	70,373	70,492	70,710	71,075	131,875

Fiscal years (OVID's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(81,036)	122,835	(54,169)	(52,339)	(26,433)	(17,414)
Stock-based compensation	7,525	5,054	6,557	7,285	6,276	4,807
Depreciation and amortization	307	237	513	568	613	273
Net cash from operating activities	(51,584)	118,612	(55,227)	(45,781)	(55,956)	(38,334)
Purchases of property and equipment	127	184	1,224	40	71	0
Net cash from investing activities	34,648	(1,821)	(87,883)	(2,581)	54,594	(49,854)
Proceeds from issuing common stock	46,731	0	—	—	—	—
Net cash from financing activities	47,072	904	181	30,535	622	75,207
Net change in cash	30,137	117,694	(142,930)	—	(740)	(13,148)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026
Astria Therapeutics	96,280	706	(32,295)*	57.1M	7.1 quarters	Q3 FY25 10-QSep 30, 2025
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.